White Papers, Case Studies, Reports

Clinical data doesn't need to be perfect for AI to deliver value. Learn a practical framework for deploying agentic AI in clinical trials today.

‍

According to seven different market research organizations, the “Agentic AI in clinical trials market” is expected to grow at a compound annual growth rate (CAGR) of anywhere between 12.5% to 43%. While the estimates obviously vary depending on who you ask, one thing remains crystal clear, agentic AI in clinical trials isn’t slowing down. As sponsors and CROs increasingly implement artificial intelligence, many organizations approaching clinical AI face real anxiety about the clinical trustworthiness of AI.

With GLP-1 therapies reshaping the competitive landscape, sponsors need speed to first patient, portfolio consistency, and adherence that holds up over years, not weeks. See how five sponsors/CROs got there with Medable.

Learn how a top-10 global pharmaceutical company partnered with Medable to rapidly expand the number of oncology trials it could concurrently conduct.

‍

Discover how AI-enabled eCOA and agentic workflows reduce clinical trial startup time, translation cycles, and meeting overhead—cutting eCOA build timelines from 16–20 weeks to under 8 weeks.

Discover how Medable’s AI-powered oncology platform simplifies complex cancer trials by integrating eCOA, ePRO, and eConsent solutions—reducing trial time, improving patient retention, and enhancing data quality for faster, more efficient research.

‍

It has become clear that our industry has reachedthe limits of human-only clinical development. As clinical trials have become increasingly complex, the endeavors that people alone can perform are no longer sufficient to generate the momentum needed to address the growing burden of human disease. This has led to longer drug development timelines and significant delays for patients. One large are of lost time is “white space,” definied simply as unproductive time caused by manual, sequential processes and fragmented data systems. Thankfully, a solution lies in agentic AI and its abilities to perform series of tasks.

The successful integration of AI agents in enterprise operations requires a balanced, deliberate approach. Drawing from recent research in Strategic Integration (SI) and agentic AI adoption within large enterprises, the following best practices help maximize value, manage change effectively, and mitigate common pitfalls. Medable Agent Studio specifically streamlines this process by providing robust tools, no-code simplicity, and built-in compliance and security standards.

‍

AI agents can play a range of roles, from acting as intelligent collaborators alongside people to independently executing entire workflows. Rooted in the principles of agentic AI, they excel at reasoning through problems, self-directing activities, and adapting to evolving contexts. Whether deployed to support individuals or to autonomously carry out operational tasks, agents enhance productivity, decision-making, and overall efficiency across a broad spectrum of use cases.

Agent Studio reimagines the clinical trial lifecycle, automating slow, manual processes, removing barriers in the clinical process, and introducing new ways to achieve clinical goals like never before. This first-of-its-kind, AI-powered, no-code platform lets you deploy ready-to-go agents trained as clinical development experts or create bespoke ones using your own data and expertise, unlocking endless possibilities.

In a rapidly changing research landscape, leaders at Takeda, Novartis, Sanofi, Daiichi Sankyo, and Medable share firsthand insights into how artificial intelligence is reshaping clinical trial operations.

This exclusive whitepaper explores how forward-thinking organizations are reimagining trial design, execution, and scaling to meet the demands of speed, precision, and patient-centricity across their entire portfolio.

‍

Learn how digital tools ease oncology research for all stakeholders while accelerating the pace of research with this whitepaper.

‍